Krebs Biochemicals and Industries Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 26, 2025
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Krebs Biochemicals held its 33rd AGM on September 26, 2025, at 11:30 a.m. at its registered office in Andhra Pradesh, with the meeting concluding at 11:55 a.m. All directors, including the Chairman of the Audit and Nomination & Remuneration Committees, the CFO, and the Company Secretary, were present. Shareholders were given e-voting facilities from September 23 to September 25, 2025, with the cut-off date set at September 19, 2025. Nine agenda items were tabled, including adoption of FY25 audited financials, re-appointment of two retiring directors (Mr. Avinash Ravi and Mr. Pabitrakumar K Bhattacharyya), appointment of statutory auditors, appointment of Mr. Manish Kumar Jain as Director and Managing Director & CEO, approval of related party transactions with Ipca Laboratories Limited, ratification of cost auditors' remuneration, and appointment of DSMR & Associates as Secretarial Auditor for five years. No questions were raised by shareholders during the meeting, and voting results will be declared once the scrutinizer's report is received.
The AGM proceedings are procedural and largely non-impactful in the short term. The key items to watch are the appointment of Mr. Manish Kumar Jain as Managing Director & CEO and the related party transaction approval with Ipca Laboratories, which could signal strategic alignment. Voting results on these resolutions are pending and may influence investor sentiment once declared.